European Journal of Cancer Abstract Book European Cancer Congress, Amsterdam 27 September

1055 Pages·2013·23.54 MB·English

Vol. 49 Supplement 2
September 2013
ISSN 0959-8049
European Journal of Cancer
Abstract Book
European Cancer Congress, Amsterdam
27 September – 1 October 2013
Disclaimer
All advertising material in this publication is expected to conform to ethical (medical) standards, and does not constitute a guarantee or
endorsementofthequalityorvalueofsuchproductortheclaimsmadeofitbyitsmanufacturer,andisintendedforprescribinghealthcare
professionalsonly.
NoresponsibilityisassumedbythePublisherforanyinjuryand/ordamagetopersonsorpropertyasamatterofproductsliability,negligence
orotherwise,orfromanyuseoroperationofanymethods,products,instructionsorideascontainedinthematerialherein.Becauseofrapid
advancesinthemedicalsciences,inparticular,independentverificationofdiagnosesanddrugdosagesshouldbemade.
Amsterdam • Boston • London • New York • Oxford • Paris • Philadelphia • San Diego • St Louis
EQUIPPED WITH
NEXT-GENERATION
SEQUENCING
Decode each patient’s tumour —
individualise cancer treatment.
(cid:116) Provides a rationale for making
your next treatment decision
(cid:116) Helps determine which drugs
to avoid
(cid:116) Identifies therapies which may
not have been considered
For example when:
(cid:102) Choosing amongst standards treatments
(cid:102) Standard treatments are not enough
(cid:102)(cid:3)Faced with rare or aggressive tumours
EXHIBITOR SPOTLIGHT THEATRE
SEPTEMBER 29TH AT 12:30 (ROOM 2)
| CarisLifeSciences.eu
VISIT CARIS LIFE SCIENCES AT BOOTH NUMBER 2400 TO FIND OUT MORE
European Journal of Cancer
Editor-in-Chief: AlexanderM.M.Eggermont
InstitutGustaveRoussy
Villejuif,France
Editors:
BasicandPreclinicalResearch: RichardMarais,Manchester,UK
GiorgioParmiani,Milan,Italy
DrugDevelopment: Jean-CharlesSoria,Villejuif,France
EarlyBreastCancer: KathleenI.Pritchard,Toronto,Canada
AdvancedBreastCancer: DavidCameron,Edinburgh,UK
GastrointestinalCancers: EricVanCutsem,Leuven,Belgium
MichelDucreux,Villejuif,France
GenitourinaryCancers: CoraSternberg,Rome,Italy
LungCancer: MaryO’Brien,London,UK
GynaecologicalCancers: IgnaceVergote,Leuven,Belgium
HeadandNeckCancer: KevinHarrington,London,UK
Sarcomas: Jean-YvesBlay,Lyon,France
Melanoma: DirkSchadendorf,Essen,Germany
Neuro-oncology: RogerStupp,Zurich,Switzerland
EpidemiologyandPrevention: JanWillemCoebergh,Rotterdam,TheNetherlands
PaediatricOncology: RobPieters,Rotterdam,TheNetherlands
FoundingEditor: HenriTagnon
PastEditors: MichaelPeckham,London,UK;Hans-Jo¨rgSenn,StGallen,Switzerland;JohnSmyth,Edinburgh,UK
EditorialOffice: Elsevier,TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UK
Tel:[phone],Email:[email protected]
EDITORIALBOARD
CLINICALONCOLOGY
J.-P.Armand(France) G.Ferrandina(Italy) P.O’Dwyer(USA)
A.Ayhan(Japan) H.Gabra(UK) J.Overgaard(Denmark)
R.Blamey(UK) H.Gelderblom(TheNetherlands) N.Pavlidis(Greece)
M.Bolla(France) B.Hasan(Belgium) J.Perry(Canada)
J.Boyages(Australia) J.C.Horiot(Switzerland) P.Price(UK)
N.Bru¨nner(Denmark) C.Huber(Germany) D.Raghavan(USA)
F.Cardoso(Portugal) R.Jakesz(Austria) J.Ringash(Canada)
J.Cassidy(UK) J.Jassem(Poland) J.Robert(France)
M.Castiglione(Switzerland) D.Jodrell(UK) A.Rody(Germany)
L.Cataliotti(Italy) V.C.Jordan(USA) D.Sargent(USA)
L.Cheng(USA) A.Katz(Brazil) M.Schmidinger(Austria)
H.Cody(USA) M.Kaufmann(Germany) S.Sleijfer(TheNetherlands)
R.Coleman(UK) I.Kunkler(UK) P.Sonneveld(TheNetherlands)
A.Costa(Italy) L.Lindner(Germany) A.Sparreboom(USA)
J.DeBono(UK) P.E.Lønning(Norway) M.vandenBent(TheNetherlands)
M.J.A.DeJong(TheNetherlands) P.Lorigan(UK) M.VanGlabbeke(Belgium)
E.deVries(TheNetherlands) K.McDonald(Australia) G.Velikova(UK)
A.Dicker(USA) R.Mertelsmann(UK) U.Veronesi(Italy)
R.Dummer(Switzerland) F.Meunier(Belgium) A.Vincent-Salomon(France)
F.Eisinger(France) T.Mok(HongKong) A.Voogd(TheNetherlands)
S.Erridge(UK) D.Nam(Korea) E.Winquist(Canada)
BASIC,PRECLINICALANDTRANSLATIONALRESEARCH
A.Albini(Italy) A.Gescher(UK) A.Puisieux(France)
P.Allavena(Italy) R.Giavazzi(Italy) V.Rotter(Israel)
F.Balkwill(UK) I.Hart(UK) M.Schmitt(Germany)
M.Barbacid(Spain) W.Keith(UK) C.G.J.Sweep(TheNetherlands)
M.Broggini(Italy) L.A.Kiemeney(TheNetherlands) G.Taraboletti(Italy)
C.Catapano(Switzerland) J.Lunec(UK) P.Vineis(UK)
J.Collard(TheNetherlands) D.R.Newell(UK) N.Zaffaroni(Italy)
E.Garattini(Italy) G.J.Peters(TheNetherlands)
EPIDEMIOLOGYANDPREVENTION
B.Armstrong(Australia) A.Green(Australia) S.Sanjose(Spain)
P.Autier(France) K.Hemminki(Germany) M.K.Schmidt(TheNetherlands)
J.M.Borras(Spain) C.Johansen(Denmark) H.Storm(Denmark)
C.Bosetti(Italy) L.A.Kiemeney(TheNetherlands) L.V.vandePoll-Franse(TheNetherlands)
J.Faivre(France) M.Maynadie´ (France) H.M.Verkooijen(TheNetherlands)
S.Franceschi(France) H.Møller(UK) R.Zanetti(Italy)
D.Forman(France) P.Peeters(TheNetherlands)
PAEDIATRICONCOLOGY
C.Bergeron(France) G.Chantada(Argentina) L.Sung(Canada)
A.Biondi(Italy) F.Doz(France) M.vandenHeuvel-Eibrink(TheNetherlands)
E.Bouffet(Canada) A.Ferrari(Italy) M.vanNoesel(TheNetherlands)
M.Cairo(USA) M.A.Grootenhuis(TheNetherlands)
H.Caron(TheNetherlands) K.Pritchard-Jones(UK)
Integrate
Streamline
Optimize
Be Integrated
Varian Medical Systems International AG www.varian.com/aria
Zug, Switzerland [email protected]
Phone +41(cid:2)-(cid:2)41(cid:2)-749 88 44
European Journal of Cancer
including EJC Supplements
AimsandScope
TheEuropeanJournalofCancer(includingEJCSupplements)isaninternationalmultidisciplinaryoncologyjournalthatpublishesoriginal
research, editorial comments, review articles and news on basic and preclinical research, clinical oncology (medical, paediatric,
radiation,surgical),translationaloncologyandoncancerepidemiologyandprevention.
ForafullandcompleteGuideforAuthors,pleasegotohttp://www.ejcancer.com
Publishing&AdvertisingOffices:ElsevierLtd,TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UK.(01865843000).
Advertisinginformation.Advertisingordersandinquiriescanbesentto:USA,CanadaandSouthAmerica:PatHamptonAdvertising
Department,ElsevierInc.,360ParkAvenueSouth,NewYork,NY10010-1710,USA;phone:[phone];fax:[phone];
e-mail:[email protected]:AdvertisingSales:ElsevierPharmaSolutions;32JamestownRoad,LondonNW1
7BY,UK;Tel.:[phone];fax:[phone];e-mail:[email protected].
Publication information: European Journal of Cancer (ISSN 0959-8049). For2013, volume 49 (18 issues) is scheduled for publication.
SubscriptionpricesareavailableuponrequestfromthePublisherorfromtheElsevierCustomerServiceDepartmentnearestyouor
fromthisjournal’swebsite(http://www.elsevier.com/locate/ejca).FurtherinformationisavailableonthisjournalandotherElsevier
productsthroughElsevier’swebsite(http://www.elsevier.com).Subscriptionsareacceptedonaprepaidbasisonlyandareenteredon
acalendaryearbasis.Issuesaresentbystandardmail(surfacewithinEurope,airdeliveryoutsideEurope).Priorityratesareavailable
uponrequest.Claimsformissingissuesshouldbemadewithinsixmonthsofthedateofdespatch.
Orders,claims,andjournalinquiries:pleasecontacttheElsevierCustomerServiceDepartmentnearestyou:
St.Louis:ElsevierCustomerServiceDepartment,3251RiverportLane,MarylandHeights,MO63043,USA;phone:[phone][toll
freewithintheUSA];([phone][outsidetheUSA];fax:[phone];e-mail:[email protected].
Oxford:ElsevierCustomerServiceDepartment,TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UK;phone:(+44)(1865)
843434;fax:[phone];e-mail:[email protected].
Tokyo:ElsevierCustomerServiceDepartment,4FHigashi-Azabu,1-ChomeBldg,1-9-15Higashi-Azabu,Minato-ku,Tokyo106-0044,
Japan;phone:[phone];fax:[phone];e-mail:[email protected].
Singapore:ElsevierCustomerServiceDepartment,3KillineyRoad,#08-01WinslandHouseI,Singapore239519;phone:[phone];
fax:[phone];e-mail:[email protected].
Authorinquiries
Forinquiriesrelatingtothesubmissionofarticles(includingelectronicsubmission)pleasevisitthisjournal’shomepageathttp://
www.elsevier.com/locate/ejca. Fordetailed instructions on thepreparation of electronicartwork, pleasevisit http://www.elsevier.
com/artworkinstructions.Contactdetailsforquestionsarisingafteracceptanceofanarticle,especiallythoserelatingtoproofs,will
beprovidedbythepublisher.Youcantrackacceptedarticlesathttp://www.elsevier.com/trackarticle.YoucanalsocheckourAuthor
FAQsathttp://www.elsevier.com/authorFAQand/orcontactCustomerSupportviahttp://support.elsevier.com.
Languageservices.PleasewriteyourtextingoodEnglish(AmericanorBritishusageisaccepted,butnotamixtureofthese).Authors
whofeeltheirEnglishlanguagemanuscriptmayrequireeditingtoeliminatepossiblegrammaticalorspellingerrorsandtoconform
to correct scientific English may wish to use the English Language Editing service available from Elsevier’s WebShop http://
webshop.elsevier.com/languageediting/orvisitourcustomersupportsitehttp://support.elsevier.comformoreinformation.
Fundingbodyagreementsandpolicies.Elsevierhasestablishedagreementsanddevelopedpoliciestoallowauthorswhosearticles
appearinjournalspublishedbyElsevier,tocomplywithpotentialmanuscriptarchivingrequirementsasspecifiedasconditionsof
theirgrantawards.Tolearnmoreaboutexistingagreementsandpoliciespleasevisithttp://www.elsevier.com/fundingbodies.
USA mailing notice: EuropeanJournalofCancer(ISSN0959-8049)ispublishedmonthlywithextraissuesinJanuary,March,May,July,
September,NovemberbyElsevierLtd.(TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UK).PeriodicalspostagepaidatJamaica,NY
11431andadditionalmailingoffices.
USAPOSTMASTER:SendchangeofaddresstoEuropeanJournalofCancer,ElsevierCustomerServiceDepartment,3251RiverportLane,
MarylandHeights,MO63043,USA.
AIRFREIGHTANDMAILINGinUSAbyAirBusinessLtd.,c/oWorldnetShippingInc.,156-15,146thAvenue,2ndFloor,Jamaica,NY11434,USA.
Copyright(cid:2)2013ECCO–theEuropeanCanCerOrganisation.Allrightsreserved
ThisjournalandtheindividualcontributionscontainedinitareprotectedundercopyrightbytheEuropeanCanCerOrganisationand
thefollowingtermsandconditionsapplytotheiruse:
Photocopying.Singlephotocopiesofsinglearticlesmaybemadeforpersonaluseasallowedbynationalcopyrightlaws.Permissionof
thePublisherandpayment of afee is required forallother photocopying,includingmultipleor systematic copying,copyingfor
advertisingorpromotionalpurposes,resale,andallformsofdocumentdelivery.Specialratesareavailableforeducationalinstitutions
thatwishtomakephotocopiesfornon-profiteducationalclassroomuse.
Forinformationonhowtoseekpermissionvisitwww.elsevier.com/permissionsorcall([phone](UK)/([phone](USA).
Derivativeworks.Subscribersmayreproducetablesofcontentsorpreparelistsofarticlesincludingabstractsforinternalcirculation
withintheirinstitutions.PermissionofthePublisherisrequiredforresaleordistributionoutsidetheinstitution.
Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult
www.elsevier.com/permissions).
Electronicstorageorusage.PermissionofthePublisherisrequiredtostoreoruseelectronicallyanymaterialcontainedinthisjournal,
includinganyarticleorpartofanarticle(pleaseconsultwww.elsevier.com/permissions).
Exceptasoutlinedabove,nopartofthispublicationmaybereproduced,storedinaretrievalsystemortransmittedinanyformorby
anymeans,electronic,mechanical,photocopying,recordingorotherwise,withoutpriorpermissionofthePublisher.
Notice.NoresponsibilityisassumedbythePublisherforanyinjuryand/ordamagetopersonsorpropertyasamatterofproducts
liability, negligence orotherwise,or from any use oroperationof any methods, products, instructions or ideas contained in the
materialherein.Becauseofrapidadvancesinthemedicalsciences,inparticular,independentverificationofdiagnosesanddrug
dosagesshouldbemade.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not
constituteaguaranteeorendorsementofthequalityorvalueofsuchproductoroftheclaimsmadeofitbyitsmanufacturer.
ThepaperusedinthispublicationmeetstherequirementsofANSI/NISOZ39.48-1992(PermanenceofPaper).
Join prIME Oncology

at the Official European Cancer Congress 2013
Sponsored Satellite Symposia
HEMATOLOGIC MALIGNANCIES * 11.00 - 13.00 * Hall G106
2 7 (cid:116) Refining Therapeutic Strategies in CD30-Positive Lymphomas
Chair: Timothy Illidge, MD, PhD

BREAST CANCER * 14.00 - 15.30 * Hall G102
S E P T E M B E R (cid:116) Strategic Options in Hard-to-Treat Advanced Breast Cancer:
Triple-Negative and Other HER2-Negative Cases
Co-Chairs: Angelo Di Leo, MD, PhD, and Vivianne Tjan-Heijnen, MD, PhD
FRIDAY
GASTROINTESTINAL MALIGNANCIES * 17.00 - 18.30 * Hall 3-1
(cid:116) Sharpening the Focus on Pancreatic Adenocarcinoma
Co-Chairs: Volker Heinemann, MD, and Dirk Richel, MD

GASTROINTESTINAL MALIGNANCIES * 17.00 - 19.00 * Hall G104

(cid:116) How I Treat Metastatic Colorectal Cancer in 2013
2 8 Chair: Aimery de Gramont, MD, PhD

SEPTEMBER
BREAST CANCER * 18.30 - 20.00 * Hall G104
(cid:116) Contemporary Management of Breast Cancer:
SATURDAY
A Focus on Innovator and Biosimilar Therapeutic Antibodies
Chair: Javier Cortés, MD, PhD
29

SEPTEMBER
GENITOURINARY MALIGNANCIES * 18.30 - 20.00 * Hall G104
(cid:116) Treating Castration-Resistant Prostate Cancer:
SUNDAY A Work in Progress
Chair: Bertrand Tombal, MD, PhD
30

SEPTEMBER
GLIOBLASTOMA * 18.30 - 20.00 * Elicium 1
MONDAY (cid:116) Therapeutic Trends in Newly Diagnosed Glioblastoma:
In Pursuit of Improved Patient Outcomes
Chair: Michael Weller, MD
www.prIMEoncology.org
Peer Review Policy for the European Journal of Cancer (EJC)
Thepracticeofpeerreviewistoensurethatonlygoodscience process.Reviewersarerequestedtorefrainfromgivingtheir
is published. It is an objective process at the heart of good personalopinioninthe‘‘ReviewerblindcommentstoAuthor’’
scholarly publishing and is carried out by all reputable sectionoftheirreviewonwhetherornotthepapershouldbe
scientific journals. Our reviewers therefore play a vital role published. Personal opinions can be expressed in the
in maintaining the high standards of the European Journal of ‘‘ReviewerconfidentialcommentstoEditor’’section.
Cancer(EJC)andallmanuscriptsarepeerreviewedfollowing
Howlongdoesthepeerreviewprocesstake?
theprocedureoutlinedbelow.
Typicallythe manuscript will be reviewedwithin 2-8 weeks.
Initialmanuscriptevaluation
Should the reviewers’ reports contradict one another or a
The Editors first evaluate all manuscripts. In some circum- reportisunnecessarilydelayedafurtherexpertopinionwill
stancesitisentirelyfeasibleforanexceptionalmanuscriptto be sought. Revised manuscripts are usually returned to the
be accepted at this stage. Those rejected at this stage are Editors within 3 weeks and the Editors may request further
insufficientlyoriginal,haveseriousscientificflaws,havepoor advice from the reviewers at this time. The Editors may
grammar or English language, or are outside the aims and requestmorethanonerevisionofamanuscript.
scopeofthejournal.Thosethatmeettheminimumcriteria
Finalreport
arepassedontoexpertsforreview.
Afinaldecisiontoacceptorrejectthemanuscriptwillbesent
Authorsofmanuscriptsrejectedatthisstagewillbeinformed
totheauthoralongwithanyrecommendationsmadebythe
within2weeksofreceipt.
reviewers, and may include verbatim comments by the
TypeofPeerReview reviewers.
The EJC employs single blind review, where the reviewer Editor’sDecisionisfinal
remainsanonymoustotheauthorsthroughouttheprocess.
ReviewersadvisetheEditors,whoareresponsibleforthefinal
Howthereviewerisselected decisiontoacceptorrejectthearticle.
Reviewers are matched to the paper according to their
SpecialIssues/ConferenceProceedings
expertise. Our reviewer database contains reviewer contact
detailstogetherwiththeirsubjectareasofinterest,andthisis Special issues and/or conference proceedings may have
constantlybeingupdated. different peer review procedures involving, for example,
GuestEditors,conferenceorganisersorscientificcommittees.
Reviewerreports
Authorscontributingtotheseprojectsmayreceivefulldetails
Reviewersareaskedtoevaluatewhetherthemanuscript: ofthepeerreviewprocessonrequestfromtheeditorialoffice.
– Isoriginal BecomingaReviewerfortheEJC
– Ismethodologicallysound
IfyouarenotcurrentlyareviewerfortheEJCbutwouldliketo
– Followsappropriateethicalguidelines
be considered as a reviewer for this Journal, please contact
– Has results which are clearly presented and support the
the editorial office by e-mail at [email protected], and
conclusions
provideyourcontactdetails.Ifyourrequestisapprovedand
– Correctlyreferencespreviousrelevantwork
youareaddedtotheonlinereviewerdatabaseyouwillreceive
Reviewers are not expected to correct or copyedit manu- aconfirmatoryemail,askingyoutoadddetailsonyourfield
scripts. Language correction is not part of the peer review ofexpertise,intheformatofsubjectclassifications.

The European Cancer Congress 2013
C. van de Velde ECCO President and Congress Chair
M. Piccart ESMO President
C. Sternberg Co-Scientific Chair
J. Yarnold Co-Scientific Chair
M. Verheij National Organising Committee Chair